We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.35 | -3.59% | 9.40 | 9.30 | 9.50 | 10.00 | 9.50 | 9.55 | 4,969,033 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.69 | 55.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/12/2007 12:01 | Very interesting RNS. Never heard of these chaps before-worth researching I think! | tonyx | |
10/12/2007 11:47 | number 1!!! | sawbones1 | |
10/12/2007 11:31 | For Immediate Release 10 December 2007 e-Therapeutics plc ("e-Therapeutics" or "the Company") Successful completion of preclinical efficacy and resistance studies of candidate antibiotic ETX1153 against MRSA e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, is pleased to announce the successful completion of preclinical studies of efficacy and rates of resistance of its candidate antibacterial drug compound ETX1153 against methicillin-resistan in lay terms as one of the hospital "superbugs". High potency ETX1153 has been tested in vitro against numerous strains of MRSA, including the vancomycin intermediately sensitive (VISA) and vancomycin resistant strains (VRSA). ETX1153 was found to be highly potent, with a Minimum Inhibitory Concentration (MIC) below 0.25 microgram/ml for all but three strains tested, for which the median MIC was 0.5 microgram/ml. The most common epidemic strain of MRSA in the UK is EMRSA-16, and this was among the strains killed most effectively at the lowest concentration. Furthermore the potency of ETX1153 was compared with that of other antibiotics commonly used against MRSA, such as moxifloxacin, trovafloxacin, ciprofloxacin, quinupristin/dalfopr linezolid, teichoplanin and vancomycin, and determined to be significantly greater, showing the lowest MICs among these drugs. Low rate of resistance emergence Initial laboratory studies conducted by e-Therapeutics in 2006 suggested that the rate of resistance development of bacteria to ETX1153 was very much lower than that to vancomycin. Quantitative comparative studies of the rate of resistance development, comparing ETX1153 with two antibiotics frequently prescribed for MRSA, mupirocin and ciprofloxacin, have confirmed this low rate of resistance. In a study involving 10 common strains of MRSA and a widely-accepted industry model for inducing bacterial resistance, resistant mutants emerged in all the samples for mupirocin and ciprofloxacin, but for 4 out of 10 samples for ETX1153 no resistant mutants were observed whatsoever. Across the other samples, the rate of development of resistance to ETX1153 was orders of magnitude slower than for these frequently prescribed antibiotics. Professor Malcolm Young, Chief Executive of e-Therapeutics commented: "We are delighted that these rigorous studies have confirmed our initial belief that ETX1153 could become an important weapon in the battle against this devastating bacterial infection. We will aim to progress to clinical studies with ETX1153 as quickly as possible." | kegs-on-legs |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions